Drug

HutchMed's SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC
Academic conferenceCancer

HutchMed’s SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC

HutchMed (China) Limited (NASDAQ: HCM; HKG: 0013) announced positive results from the SANOVO Phase III study in China, showing that ORPATHYS (savolitinib) in combination with TAGRISSO (osimertinib) demonstrated a statistically…

Astellas' Non-Hormonal VEOZA Gains NMPA NDA Acceptance for Menopausal Hot Flashes in China

Astellas’ Non-Hormonal VEOZA Gains NMPA NDA Acceptance for Menopausal Hot Flashes in China

Sino Biopharmaceutical's CTTQ Earns Dual CDE Breakthrough Therapy Designations for TQ-A3334 and TQA3605 in Chronic Hepatitis B

Sino Biopharmaceutical’s CTTQ Earns Dual CDE Breakthrough Therapy Designations for TQ-A3334 and TQA3605 in Chronic Hepatitis B

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Biogen and City Therapeutics Collaborate on RNAi Therapies for CNS Diseases
BiogenCity Therapeutics

Biogen and City Therapeutics Collaborate on RNAi Therapies for CNS Diseases

AstraZeneca's Imfinzi Gets Positive Opinion for Bladder Cancer Perioperative Treatment
AstraZenecaCancer

AstraZeneca’s Imfinzi Gets Positive Opinion for Bladder Cancer Perioperative Treatment

EyePoint's Partner Betta Completes Enrollment for Duravyu's Pivotal Phase III Study
Betta PharmaceuticalsClinical trial approval / initiation

EyePoint’s Partner Betta Completes Enrollment for Duravyu’s Pivotal Phase III Study

EMA Recommends Tevimbra for Nasopharyngeal Cancer First-line Treatment
BeiGeneBeOne Medicines

EMA Recommends Tevimbra for Nasopharyngeal Cancer First-line Treatment

Show More